SpliceBio secured $135 million in Series B financing from major pharma venture arms, propelling clinical development of a pioneering dual AAV gene therapy for Stargardt disease. This substantial capital infusion underscores robust investor confidence and sets the stage for critical clinical progress in treating inherited blindness.